logo

Compugen Ltd (CGEN)



Trade CGEN now with
  Date
  Headline
4/14/2020 7:02:42 AM Compugen To Present Data Update On COM701 Phase 1 Clinical Trial At The 2020 AACR Virtual Annual Meeting
4/6/2020 7:01:41 AM Compugen Announces First Patient Dosed In COM902 Phase 1 Trial For Patients With Advanced Malignancies
3/17/2020 7:06:13 AM Compugen Announces Closing Of Public Offering Of 8.33 Mln Ordinary Shares At $9/Shr
3/12/2020 6:06:56 AM Compugen Prices Public Offering Of 8.33 Mln Ordinary Shares At $9.00 Per Share
3/9/2020 7:12:31 AM Compugen Announces Updated Clinical Data From Ongoing COM701 Phase 1 Study
2/20/2020 7:31:21 AM Compugen Q4 Net Loss $6.5 Mln Or $0.10/Shr Vs Loss Of $9.4 Mln Or $0.16/Shr Last Year
2/20/2020 7:23:44 AM Compugen Announces Phase 1/2 Triple Combination Study To Evaluate COM701 With Opdivo And TIGIT Inhibitor
2/7/2020 7:03:12 AM Compugen Presents Update On COM701 Phase 1 Trial At ASCO-SITC Clinical Immuno-oncology Symposium
2/4/2020 7:11:31 AM Compugen Unveils New U.S. Patent For Methods Of Screening For Anti-PVRIG Antibodies
1/8/2020 7:07:11 AM Compugen Names Oliver Froescheis SVP, Corporate And Business Development
11/11/2019 7:04:26 AM Compugen Q3 Net Loss $6.5 Mln Or $0.1/shr Vs. Loss $3.1 Mln Or $0.05/shr Prior Year
11/11/2019 7:00:00 AM Compugen Reports Third Quarter 2019 Results (Press Release)
11/4/2019 7:17:23 AM Compugen Announces FDA Clearance Of IND Application For COM902